CELSIS
Celsis, the global leader in rapid microbial testing systems for industry, today introduced the Celsis Accel system, the most robust and easiest-to-use rapid microbial screening system for small and medium-size manufacturing companies.
Utilizing Celsis’ proprietary reagent technology, the Celsis Accel system reduces time necessary for quality control assessment of microbial contamination. This shortens production cycle times by lowering quarantined inventory levels awaiting quality control release and reduces working capital requirements. Faster quality control results also provide an earlier indication of contamination allowing a faster and more effective investigation and corrective action, thereby reducing the economic impact of the event.
Using its Financial Impact Assessment (FIA) , Celsis works with hundreds of manufacturing facilities around the world to evaluate the cost savings of implementing a Celsis system. Utilizing company specific information including the value of products and the time and cost comparisons associated with the Celsis method, the FIA projects the 5-year Net Present Value (NPV) of a company’s investment in the Celsis system. The 5-year NPV for the average manufacturing facility is typically in excess of $300,000.
The Celsis Accel takes the robustness and ease-of-use of the widely adopted Celsis Advance platform packaged into a compact system specifically designed for small and medium-size manufacturing facilities. Easy-to-use, easy-to-learn software makes the Celsis Accel a great fit for Home, Beauty and Pharmaceutical product manufacturers’ busy microbiology labs.
To read more about the new Celsis Accel system online, please visit celsis.com/Accel
“Celsis works with product manufacturers of all sizes. Small and medium-size manufacturers have different testing requirements than large manufacturers and were asking for an instrument designed to meet their needs,” said Jay LeCoque, CEO. “Responding to this demand, we developed the Accel for manufacturers whose testing requirements are smaller, but we employed the same robustness and ease-of-use of our popular large capacity Advance platform.”
To allow maximum flexibility with sample size and sensitivity, Celsis adapted the familiar sample tube platform to a precision movement carousel for easy loading and speedy processing with the ability to run 30 assays at a time. A fourth injector position gives the system flexibility to use new reagent technologies as they are developed. From reagent bottle access to sample loading, the ergonomic design puts everything easily at the fingertips of the user.
Celsis Accel.im™ takes advantage of current Celsis software innovations, such as a new ribbon menu system, data security features, and the ability to export sample results. User administration features, an event log and more allow users full compliance with the FDA’s CFR 21 Part 11 and the EU’s Annex 11.
Proven rugged and reliable systems, plus dedicated global support, have made Celsis the industry standard for leading manufacturers around the world. Celsis systems are used to rapidly and effectively screen a variety of Home, Beauty and Pharmaceutical products — including body washes, lotions, soaps, toothpastes, liquid detergents, cosmetics, tablets and ointments, IV solutions and oral drug suspensions — helping companies save time and money while releasing safe products to market.
To read more about the new Accel system online, please visit celsis.com/Accel
For more information about Celsis products and services for the Home, Beauty and Pharmaceutical industries, please visit celsis.com or call +1 312 476 1282.
Contact:
Media
Celsis, Inc.
Liz Garvey, +1 312 476 1218
lgarvey@celsis.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release
Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release
New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum